SGS to expand bioanalytical testing capabilities

10 Dec 2018

The €3.5 million investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for pharmaceutical clients.

SGS is investing €3.5 million to undertake a two-phase expansion project at its laboratory in Poitiers, France, to implement a 50% increase in bioanalytical capabilities at the site by 2020.

SGS to expand bioanalytical testing capabilities

The initial phase of the project was completed in November 2018, with the delivery of a new, 150-m2 immunoassay laboratory, equipped with eight instruments (MSD, ELISA, Luminex, Ella) and with the capacity to employ 20 analysts.

The second phase of the expansion will commence with the construction of a new, 800-m2 building, housing both a new laboratory and office space, and the renovation of the existing laboratory at the site. Alongside the renovation works will be the introduction of a new electronic laboratory notebook system across the entire facility, as well as upgrades to the site's quality management system and sample automation capabilities.

Recruitment of new staff, which has seen an increase of over 25% over the past 2 years, is set to continue and will further accelerate by Q3 2019.

A4lain Renoux, Laboratory Director, said: "This major investment in equipment, facilities and expert staff will significantly increase the capabilities at the site to match increasing demand and shorten processes for our pharmaceutical clients. SGS has a commitment to offer a global presence with a center of excellence model, and it is through investment in both the state-of-the-art facilities and staff that we can meet this ambition."

Read More

Related news

Specialist API CDMO acquired by GHO Capital

Specialist API CDMO acquired by GHO Capital

16 Mar 2019

Future plan is to extend Sterling’s international presence to meet increasing demand from customers worldwide.

Read more 
Bringing next generation single-use sensor technologies to the life science market

Bringing next generation single-use sensor technologies to the life science market

14 Mar 2019

Pall and Broadley-James’ combined expertise proves complementary in addressing critical customer pain points in modern bioprocessing.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

TraceLink submits an interoperable blockchain network solution for FDA DSCSA Pilot Project Program

12 Mar 2019

Trace Histories is a purpose-built distributed ledger solution for ensuring patient safety by 2023 DSCSA deadline.

Read more 
Overcoming lyophilization challenges at Interphex 2019

Overcoming lyophilization challenges at Interphex 2019

10 Mar 2019

Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.

Read more 
Catalent invests over $27 million to commercialize Zydis Ultra

Catalent invests over $27 million to commercialize Zydis Ultra

7 Mar 2019

Zydis Ultra allows a patented and innovative drug coating to be introduced during a product’s formulation, enabling the dosage of active ingredient to be up to four times higher than a conventional Zydis ODT.

Read more 
Novel systems for membrane chromatography

Novel systems for membrane chromatography

6 Mar 2019

Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.

Read more 
Lilly to introduce lower-priced insulin

Lilly to introduce lower-priced insulin

5 Mar 2019

Authorized generic version of Humalog will be available in US pharmacies at 50% lower list price.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more